In Vitro Characterization of Hepatic Flavopiridol Metabolism Using Human Liver Microsomes and Recombinant UGT Enzymes
- 1 May 2002
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 19 (5) , 588-594
Abstract
Purpose.To assess the contribution of drug metabolism to the variability on flavopiridol glucuronidation observed in cancer patients, and to determine the ability of all known human...Keywords
This publication has 22 references indexed in Scilit:
- The legacy of pharmacogenetics and potential applicationsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001
- In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.2001
- Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.2001
- Isolation and Characterization of the UGT2B28 cDNA Encoding a Novel Human Steroid Conjugating UDP-GlucuronosyltransferaseBiochemistry, 2001
- Human UDP-Glucuronosyltransferases: Metabolism, Expression, and DiseaseAnnual Review of Pharmacology and Toxicology, 2000
- The Monkey and Human Uridine Diphosphate-Glucuronosyltransferase UGT1A9, Expressed in Steroid Target Tissues, Are Estrogen-Conjugating Enzymes*Endocrinology, 1999
- STRUCTURAL AND FUNCTIONAL STUDIES OF UDP-GLUCURONOSYLTRANSFERASES*Drug Metabolism Reviews, 1999
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.Journal of Clinical Oncology, 1998
- Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.1996
- Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates.Drug Metabolism and Disposition, 1994